Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

142 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Docetaxel plus cisplatin in recurrent and/or metastatic non-squamous-cell head and neck cancer: a multicenter phase II trial.
Imamura Y, Tanaka K, Kiyota N, Hayashi H, Ota I, Arai A, Iwae S, Minami S, Yane K, Yamazaki T, Nagatani Y, Toyoda M, Takahama T, Sakai K, Nishio K, Otsuki N, Nibu KI, Minami H. Imamura Y, et al. Among authors: yane k. Med Oncol. 2021 Sep 22;38(11):128. doi: 10.1007/s12032-021-01581-z. Med Oncol. 2021. PMID: 34550483 Clinical Trial.
Prevalence of human papillomavirus in oropharyngeal cancer: a multicenter study in Japan.
Hama T, Tokumaru Y, Fujii M, Yane K, Okami K, Kato K, Masuda M, Mineta H, Nakashima T, Sugasawa M, Sakihama N, Yoshizaki T, Hanazawa T, Kato H, Hirano S, Imanishi Y, Kuratomi Y, Otsuki N, Ota I, Sugimoto T, Suzuki S. Hama T, et al. Among authors: yane k. Oncology. 2014;87(3):173-82. doi: 10.1159/000360991. Epub 2014 Jul 12. Oncology. 2014. PMID: 25033838
Optimization of therapeutic strategy for p16-positive oropharyngeal squamous cell carcinoma: Multi-institutional observational study based on the national Head and Neck Cancer Registry of Japan.
Saito Y, Hayashi R, Iida Y, Mizumachi T, Fujii T, Matsumoto F, Beppu T, Yoshida M, Shinomiya H, Kamiyama R, Kitano M, Yokoshima K, Fujimoto Y, Hama T, Yamashita T, Okami K, Miura K, Fujisawa T, Sano D, Kato H, Minami S, Sugasawa M, Masuda M, Ota I, Iwae S, Kawata R, Monden N, Imai T, Asakage T, Okada M, Yoshikawa T, Tanioka K, Kitayama M, Doi M, Fujii S, Fujii M, Oridate N, Nakamizo M, Yoshimoto S, Homma A, Nibu KI, Yane K. Saito Y, et al. Among authors: yane k. Cancer. 2020 Sep 15;126(18):4177-4187. doi: 10.1002/cncr.33062. Epub 2020 Jul 10. Cancer. 2020. PMID: 32648953 Free article.
Lack of p16/CDKN2 alterations in thyroid carcinomas.
Yane K, Konishi N, Kitahori Y, Naito H, Okaichi K, Ohnishi T, Miyahara H, Matsunaga T, Hiasa Y. Yane K, et al. Cancer Lett. 1996 Mar 19;101(1):85-92. doi: 10.1016/0304-3835(96)04117-1. Cancer Lett. 1996. PMID: 8625287
Phase II study of the efficacy and safety of lenvatinib for anaplastic thyroid cancer (HOPE).
Higashiyama T, Sugino K, Hara H, Ito KI, Nakashima N, Onoda N, Tori M, Katoh H, Kiyota N, Ota I, Suganuma N, Hibi Y, Nemoto T, Takahashi S, Yane K, Ioji T, Kojima S, Kaneda H, Sugitani I, Tahara M. Higashiyama T, et al. Among authors: yane k. Eur J Cancer. 2022 Sep;173:210-218. doi: 10.1016/j.ejca.2022.06.044. Epub 2022 Aug 3. Eur J Cancer. 2022. PMID: 35932627 Clinical Trial.
Expression of REG III and prognosis in head and neck cancer.
Masui T, Ota I, Itaya-Hironaka A, Takeda M, Kasai T, Yamauchi A, Sakuramoto-Tsuchida S, Mikami S, Yane K, Takasawa S, Hosoi H. Masui T, et al. Among authors: yane k. Oncol Rep. 2013 Aug;30(2):573-8. doi: 10.3892/or.2013.2521. Epub 2013 Jun 5. Oncol Rep. 2013. PMID: 23743605
142 results